Abstract
Stage T1 through T3 lip cancers can be treated primarily by brachytherapy (BRTX), with or without external radiotherapy (ERT), with adequate safety margins and good results. In this study, the outcomes of BRTX were reviewed for patients treated at the Brachytherapy Department of the Istanbul University Oncology Institute (IUOE). The medical records of 41 patients registered at IUOE with a diagnosis of lip cancer between 1988 and 2003 were reviewed. The median follow-up time was 88 months (24–160 mo). Among these patients, 21 patients with a primary tumor, 14 with tumors arising postoperatively, and 6 with postoperative recurrence of tumor were treated using BRTX. A total of 33 patients (80%) received BRTX alone and 8 (20%) received BRTX and ERT. The 10-year local control rate was 100%, 93%, and 67% for patients treated with BRTX alone, BRTX and surgery, and those treated for postoperative recurrence, respectively (P < .02). For patients treated with BRTX only and BRTX plus surgery, specific disease-free survival was 95% and 94%, respectively, and overall survival was 93% and 100%, respectively; these differences were not statistically significant. One patient with a postoperative recurrence who had been treated with BRTX died as a result of lip cancer. No patients developed any ulcerations, intra-oral complications, or mandibular necrosis. In the BRTX only group, 83% had excellent or good cosmetic results. In the surgery group, 62% had a contour deformity. In lip cancer management, BRTX results were comparable for local control, survival, and minimal late effects in normal tissue. This is in accordance with current reports in the medical literature. Satisfactory results were observed in patients with stage T1 and T2 lesions who had been treated with BRTX only and in patients with stage T3 lesions who had been treated with BRTX plus ERT, without a need for additional treatment modalities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pigneux J, Richaud P, Lagarde C. The place of interstitial therapy using Ir 192 in the management of carcinoma of the lip. Cancer. 1979;43:1073–1077.
Crezo I, Liu F, Payne D. Squamous cell carcinoma of the lip: analysis of the Princess Margaret Hospital experience. Radiother Oncol. 1993;28:142–147.
Gerbaulet A, Chassagne D, Hayem M, et al. L’épithélioma la lévre serie de 355 cas. J Radiol Electrol. 1978;59:603–610.
Mazeron JJ, Richaud P. Compte rendu de la XVIII e Reunnion du Groupe Europeen de Curietherapie: session consacre aux cancer de la levre, Padua, Italy; May 1981. JE Radiother. 1984;5:50–56.
Cruse CW, Radocha RF. Squamous cell carcinoma of the lip. Plast Reconstr Surg. 1987;80:787–791.
Pitkanenen J, Lahdi A, Sundell B. Carcinoma of lip: a retrospective study of 70 patients. J Plast Reconstr Surg. 1985;19:289–294.
Nguyen TD, Douchez J, Combes J, et al. Residive tumorale pur de cancer labiaux de rattrapage par curiethérapie interstitielle. Ann Radiol. 1982;23:207–209.
Chen J, Katz R, Krutchkoff D, et al. Lip cancer. Cancer. 1992;70:2025–2030.
Megrehan DA, Roenigk RK. Management of superficial squamous cell carcinoma of the lip with Mohs micrographic surgery. Cancer. 1990;66:463–468.
Rowe DE, Carrol J, Day CL. Prognostic factors for local recurrence, metastasis and survival rates in squamous cell carcinoma of the skin ear and lip. J Am Acad Dermatol. 1992;26:976–990.
Zurrida S, Bartoli C, Bono A, et al. Outpatient surgical treatment of lip carcinoma: immediate and long-term results. Tumori. 1989;75:263–265.
Fitzpatrick PJ. Cancer of the lip. J Otolaryngol. 1984;13:32–36.
Simon JM, Mazeron JJ, Pohar S, et al. Effect of intersource spacing on local control and complications in brachytherapy of mobile tongue and floor of mouth. Radiother Oncol. 1993;26:19–25.
Hermanec P, Sobin LH, eds. UICC: TNM Classification of Malignant Tumors. 4th ed. New York, NY: Springer Verlag; 1987.
Dixon WJ. BMDP Statistical Software. Saugus, Mass: Statistical Solutions; 1992.
Pierquin B, Wilson JF, Chassagne D. Modern Brachytherapy. New York, NY: Masson Publishing; 1987.
Zitch RP. Carcinoma of the lip. Otolaryngol Clin North Am. 1993;26:265–277.
Petrovich Z, Parker RG, Luxton G, et al. Carcinoma of the lip and selected sites of head and neck skin: a clinical study of 896 patients. Radiother Oncol. 1987;8:11–17.
Beavois S, Hoffstetter S, Peiffert D, et al. Brachytherapy for lower lip epidermoid cancer: tumoral and treatment factors influencing recurrences and complications. Radiother Oncol. 1994;33:195–203.
Van Limbergen E, Ding W, Hausteermans K, et al. Lip cancer: local control results of low dose rate brachytherapy. The GEC-ESTRO 1993 survey of 2800 cases. Presented at: the annual GEC ESTRO meeting; Venice, Italy; 1993.
Mazeron JJ, Noel G, Simon JM. Head and neck brachytherapy. Semin Radiat Oncol. 2002;12:95–108.
Gerbaulet A, Pötter R, Mazeron JJ, et al. The GEC ESTRO Handbook of Brachytherapy. Leuven, Belgium; ACCO;2002.
Heller KS, Shah JP. Carcinoma of the lip. Am J Surg. 1979;138:600–603.
de Visscher J, Gronde S, Brotke G, et al. Results of radiotherapy for squamous cell carcinoma of the vermilion border of the lower lip: a retrospective analysis of 108 patients. Radiother Oncol. 1996;39:9–14.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aslay, I., Küçücük, S., Kemikler, G. et al. Effectiveness of brachytherapy in the treatment of lip cancer: A retrospective study at the Istanbul University Oncology Institute. Adv Therapy 22, 395–406 (2005). https://doi.org/10.1007/BF02850086
Issue Date:
DOI: https://doi.org/10.1007/BF02850086